Outro raises $7M to help Americans taper off psychiatric medications

Outro, which describes itself as the first neuroscience-based platform helping Americans safely discontinue psychiatric medications, has raised $7 million, the company announced.

The capital came across pre-seed and seed rounds rather than a single financing, according to the announcement. The round drew participation from Listen Ventures, Cake Ventures, Jason Calicanis's LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group, Pave Health Ventures, and more investors.

No single lead investor was identified in the announcement, and the company did not disclose how it intends to deploy the proceeds.

The funding lands in a corner of healthcare that sits awkwardly between psychiatry and primary care. Outro's pitch rests on the premise that the medical system is organized around starting psychiatric medications, not stopping them — leaving patients who want to come off antidepressants to manage withdrawal largely on their own. The company positions its offering as a neuroscience-based alternative to that gap.

Outro's New York base and its framing as a "platform" put it among a small group of ventures built specifically around deprescribing rather than prescribing. That distinction matters commercially: the patients it targets are, by definition, already in the healthcare system and already on medication, and the clinical question is how to reduce a dose safely rather than whether to begin treatment.

The announcement did not include customer figures, clinician headcount, revenue, or a valuation. It also did not specify how the pre-seed and seed tranches were split, or which of the named investors anchored either round.

With $7 million now committed across two early stages, Outro joins a set of mental-health startups betting that patients and payers will pay for structured, supervised tapering support. Whether that model scales depends on details the company has not yet made public: clinical outcomes, reimbursement, and the cost of delivering sustained one-on-one care.